Biotest AG (HAM:BIO) Notes Receivable: €0.0 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:BIO Biotest AG HAM:BIO
56 GF Score
Price €40.00
View Full Analysis

What is Biotest AG Notes Receivable?

Biotest AG HAM:BIO +2.04% 56 Notes Receivable is €0.0 Mil as of Mar. 2025. GuruFocus rates HAM:BIO with a GF Score™ of 56/100.

Biotest AG's Notes Receivable for the quarter that ended in Mar. 2025 was €0.0 Mil.

Biotest AG Notes Receivable Historical Data

* Premium members only.

The historical data trend for Biotest AG's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotest AG Notes Receivable Chart

Biotest AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Biotest AG Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HAM:BIO
56GF Score
Biotest AG HAM:BIO
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biotest AG Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.0 Mil mean?
Biotest AG (HAM:BIO) has a Notes Receivable of €0.0 Mil as of Mar. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Biotest AG and its competitors.
Is Biotest AG's Notes Receivable too high?
Biotest AG's current Notes Receivable is €0.0 Mil. Overall, Biotest AG has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Biotest AG's Notes Receivable compare to VRTX and REGN?
Biotest AG's Notes Receivable of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Biotest AG and its competitors. Biotest AG's current Notes Receivable is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotest AG stock overvalued right now?
Biotest AG (HAM:BIO) has a current Notes Receivable of €0.0 Mil. The current Notes Receivable is €0.0 Mil. Biotest AG's overall GF Score™ is 56/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Biotest AG (HAM:BIO), the current Notes Receivable is €0.0 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biotest AG Business Description

Address Landsteinerstrasse 5, PO Box 10 20 40, Dreieich, DEU, 63303
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The company covers preclinical and clinical development of the preparations, plasma collection, production, as well as marketing and sales.
56GF Score

Get the complete analysis for HAM:BIO

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€40.00
Price